Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus

NCT03010683 · Completed

Last updated 2026-05-28

This clinical trial is testing how medications that activate GLP-1 receptors affect blood vessel health in people with coronary artery disease or type 2 diabetes over 12 months.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 60 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2015-11 · est. completion 2017-12

Where 1 site · Greece

What this study is testing ClinicalTrials.gov NCT03010683 ↗

Description as written by the study sponsor.

Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity. Agonists of Glucagon like peptide - 1 receptors (GLP-1R) used in the treatment of type 2 diabetes mellitus (T2DM). This category includes exenatide and liraglutide. These drugs lower glucose levels by inhibiting the secretion of glucagon, promoting the release of insulin in response to hyperglycemia, slowing gastric emptying, and augmenting satiety. Clinical studies have shown that GLP-1R agonists have beneficial effects on cardiovascular function in both diabetic patients and healthy subjects. The purpose of this study is to investigate in patients with T2DM without coronary artery disease (CAD), patients with T2DM and CAD and obese patients with abnormal oral glucose tolerance test (OGTT), changes in arterial stiffness, endothelial glycocalyx thickness and coronary reserve flow (CFR) after treatment with metformin or agonist GLP-1R.

Treatments tested

Liraglutide also known as Victoza (liraglutide) Drug

Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
Metformin also known as Glucophage (Metformin) Drug

Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os

Main thing measured	Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.
Sponsor	University of Athens
Conditions studied	Type 2 Diabetes Mellitus, Coronary Artery Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03010683 ↗